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Previewspositive feedback loop (Figure 1). The
notion that natural specificities can have
an important effect potentially fits with
earlier experiments on the importance of
IgA in promoting mucosal antigen uptake
(Corthe´sy, 2007) and the outcome of B
cell subset transfer experiments in the
paper from Bunker et al. (2015), where
they concluded that B1 cells (but the
B1b subset rather than the B1a subset
normally associated with IgM natural
specificities) contribute to the T-cell-inde-
pendent IgA response.
Appropriately for papers in Immunity,
we are looking at the microbial dramatis
personae—who is there—determined by
the IgA response in different mouse
strains and intestinal niches. Together
they emphasize that the germline-en-
coded Ig repertoire is likely to be very
important as a starting point for host-mi-
crobial mutualism, notwithstanding clear
evidence for substantial later T-cell-
dependent diversification. Although we
can infer metabolic signatures of those418 Immunity 43, September 15, 2015 ª2015microbial taxa that are preferentially IgA
bound from their genomes, we still need
better information on how these organ-
isms actually respond to life in the intes-
tine with the challenges of nutrient and
electron acceptor limitations, bile acids,
and the consequences of quorum sensing
potentially driving symbiosis, virulence,
competence, conjugation, antibiotic pro-
duction, motility, sporulation, and biofilm
formation. We’ve come around full circle,
to a (as yet incompletely justified) belief
in the lovely idea that IgA (or IgM) actively
shapes these processes for the mutual
benefit of the host and microbiota alike.REFERENCES
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Elucidating the function of tumor-infiltrating regulatory T (Treg) cells has been difficult. In this issue of
Immunity, Joshi et al. (2015) demonstrate that Treg cells associatedwithmurine lung cancers are foundwithin
tertiary lymphoid structures and actively restrain effector T cells at the tumor site.The recent clinical success of immune-
based therapies in multiple human can-
cer types demonstrates that the immune
system can be manipulated for clinical
benefit (Page et al., 2014). This success
has triggered increased activity aimed
at understanding the inhibitory mecha-
nisms restricting anti-tumor immunity in
order to optimize clinical efficacy and
broaden the spectrum of patients who
benefit from these therapies. Front
and center in this line of inquiry are
CD4+Foxp3+ regulatory T (Treg) cells,
which are critical for the suppression of
immune responses and the maintenanceof immune homeostasis. Treg cells are
present at elevated densities in many hu-
man and murine cancers, suggesting that
these cells might play functional roles in
the tumor microenvironment. Epidemio-
logical data from human cancer studies
reveal that for some cancer types, a
high density of Treg cells within tumor
lesions is predictive of poor outcome,
whereas in other cancers, the opposite
effect is observed (deLeeuw et al.,
2012). Therefore, although it is widely
hypothesized that tumor-infiltrating Treg
cells promote tumor development by
shielding tumors from immune attack,it is equally plausible that in some can-
cer contexts, Treg cells might restrict tu-
mor development by other mechanisms,
such as suppressing tumor-promoting
inflammation. These complexities high-
light the importance of elucidating the
functional roles of tumor-infiltrating Treg
cells in different cancer types. However,
such efforts have been hampered by a
lack of approaches in tractable animal
models that enable the selective abla-
tion of Treg cells within tumor lesions
while leaving Treg cells distributed else-
where in the body untouched. In this
issue of Immunity, Joshi et al. (2015)
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Figure 1. Treg Cells Actively Restrain Effector T Cells within Tumor-Associated Tertiary
Lymphoid Structures
(Top) Treg cells associated with lung adenocarcinomas in ‘‘KP’’ mice are localized within tertiary lymphoid
structures (TLSs) positioned at the tumor margin. These structures contain dendritic cells, CD4+ and CD8+
conventional T cells, regulatory T (Treg) cells, B cells, and high endothelial venules (HEVs).
(Bottom) Local ablation of Treg cells triggers effector T cell activation in the TLS, infiltration of T cells into
the tumor, and destruction of tumor architecture.
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Previewsdemonstrate that localized Treg cell
depletion in a murine model of lung
adenocarcinoma triggers robust effector
T cell responses and tumor destruction,
suggesting that tumor-infiltrating Treg
cells actively restrain anti-tumor immunity
in this model.
Joshi et al. used a cancer model that is
initiated by intratracheal delivery of non-
replicating lentivirus expressing Cre re-
combinase into KrasLSL-G12DTrp53flox/flox
(‘‘KP’’) mice. Cre expression induces
expression of activated Kras and deletionof Trp53 in transduced cells, driving the
development of lung adenocarcinomas
(Jackson et al., 2005). In most experi-
ments, the lentivirus was also engineered
to express additional components, in-
cluding a luciferase reporter and model
T cell antigens, enabling the analysis of
antigen-specific T cell responses directed
at these tumors. In addition, mice
harbored a Foxp3DTR allele in which the
human diphtheria toxin receptor (DTR) is
expressed under the dictates of the
Foxp3 promoter, permitting the inducibleImmunity 43, Seablation of Foxp3-expressing Treg cells
by administration of diphtheria toxin
(DT). Using this system, the authors
demonstrated that systemic Treg cell
ablation unleashed robust effector T cell
responses characterized by extensive tu-
mor infiltration and destruction of tumor
architecture (Figure 1). However, it re-
mained unclear whether this effect was
due to the ablation of Treg cells within
the tumor or the widespread effects asso-
ciated with systemic Treg cell ablation.
In an effort to bypass this limitation,
the authors employed a clever trick in
which DT was administered intratra-
cheally, thereby directing the toxin to
the lung-associated tissues. This regimen
induced selective Treg cell depletion
within lung tumors and the lung-draining
mediastinal lymph nodes (presumably as
a result of lymphatic drainage of toxin
into the lymph nodes) and triggered tumor
destruction comparable to that observed
with systemic DT treatment. Further ex-
amination revealed that Treg cell ablation
induced increased proliferation of intratu-
moral T cells within 4 days, suggesting
that the activation of effector T cells was
triggered within the tumor. Despite this
evidence, it remains possible that the pro-
liferation of some of these T cells was initi-
ated outside of the tumor; experiments in
which the influx of T cells from the blood is
blocked after Treg cell ablation would
provide further insight into this issue.
Taken together, these findings suggest
that in the KP lung cancer model, Treg
cells actively restrain effector T cell re-
sponses within the tumor and that local-
ized Treg cell ablation unleashes robust
anti-tumor immune responses. Impor-
tantly, similar results were observed
for KP lung tumors that did not express
engineered antigens, indicating that the
observed tumor destruction was not
dependent on the presence of strong
model antigens.
Interestingly, the authors noted that
very few immune cells were associated
with the tumor parenchyma. Instead,
most immune cells, including Treg cells,
were found in perivascular lymphoid ag-
gregates located at the tumor margins
(Figure 1). Extensive characterization re-
vealed that these aggregates exhibited
many hallmarks of tertiary lymphoid
structures (TLSs). TLSs, so named to
distinguish them from primary lymphoid
sites (e.g., thymus and bone marrow)ptember 15, 2015 ª2015 Elsevier Inc. 419
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Previewsand secondary lymphoid organs (e.g.,
spleen, lymph nodes, and gut-associated
lymphoid tissue), are immunological out-
posts that are established on an ad hoc
basis, often at sites of chronic inflamma-
tion, infection, and cancer (Dieu-Nosjean
et al., 2014). Hallmarks of TLSs include B
cell zones, T cells zones (complete with
dendritic cells, conventional T cells, and
Treg cells), and high endothelial venules
(HEVs), which allow regulated entry of im-
mune cells from the blood into lymphoid
organs. Despite a growing body of
descriptive and correlative data regarding
tumor-associated TLSs (TA-TLSs) in hu-
man cancers (Dieu-Nosjean et al., 2014),
it has been difficult to determine the
impact of TLSs on tumor progression
and anti-tumor immunity because of a
lack of tractable cancer models in which
TA-TLSs are observed. The identification
of TA-TLSs in the KP model thus repre-
sents a substantial advance in that it
implicates TA-TLSs as important sites of
immunological activity within the tumor
environment and provides a unique plat-
form for the study of TA-TLS biology in a
tractable, physiologically relevant murine
cancer model.
The KP lung cancer model will allow
new mechanistic studies to explore a
number of interesting questions regarding
the origin and function of TA-TLSs. For
example, it is unclear why TLSs form in
some cancers and not in others and
whether TA-TLS formation is driven by tu-
mor-intrinsic or tumor-extrinsic factors. In
addition, the fact that TA-TLSs contain
HEVs suggests that TLSs could be key
portals of lymphocyte entry into tumors,
but the mechanisms regulating lympho-
cyte entry and egress from TLSs are not
well understood. Broadly speaking, basic
studies of the mechanisms underlying
TLS formation and function might provide
new insights into immune surveillance
and immune suppression within the tumor
microenvironment.
From a translational perspective, the
KPmodel could serve as a useful platform
for assessing the impact of immunother-
apies on TA-TLS structure and function
and for devising new therapeutic strate-
gies that exploit TA-TLS biology. For420 Immunity 43, September 15, 2015 ª2015example, given recent data suggesting
that anti-CTLA-4 antibody leads to cancer
regression by inducing the selective
depletion of intratumoral Treg cells and
that Treg cell depletion is dependent on
the presence of Fc-receptor-expressing
myeloid cells (Furness et al., 2014), it will
be important to determine whether anti-
CTLA-4 induces Treg cell depletion within
TA-TLSs. Moreover, given the emerging
concept that ‘‘T-cell-inflamed’’ tumors
might be more responsive to immune-
based therapy (Gajewski et al., 2013), it
will be interesting to determine whether
therapeutic manipulation could be used
for inducing the formation or expansion
of TA-TLSs and thereby augmenting the
immune presence within the tumor.
Once effector T cells are drawn into
nascent or expanded TLSs within the tu-
mor, immunotherapy could then be used
to release these cells from inhibitory
mechanisms, including Treg-cell-medi-
ated suppression.
Finally, the findings of Joshi et al. have
implications for understanding the nature
of tumor-expressed antigens that can
beeffectively recognizedby tumor-associ-
ated T cells. T cell tumor antigens can
be broadly classified as ‘‘tumor-associ-
ated’’ antigens, comprising non-mutated
self-antigens that are preferentially ex-
pressed by tumor cells, or ‘‘tumor-
specific’’ antigens, such as mutated pep-
tides (‘‘neo-antigens’’) generated by the
mutational processes underlying tumori-
genesis. The recent advent of cancer
genome sequencing and high-throughput
immunological monitoring has enabled
studies demonstrating that T cells reactive
to tumor-specific neo-antigens canbe iso-
lated from some human cancer patients
(Schumacher and Schreiber, 2015). From
findings such as these, it has been hypoth-
esized that cancers with a high frequency
of non-synonymous pointmutationsmight
be more responsive to immunotherapy
because of an increased probability of dis-
playing unique neo-antigens for recogni-
tion byeffector T cells. In the current study,
Joshi et al. demonstrate that Tregcell abla-
tion in the KP model induces immune cell
infiltration and tumor destruction, even in
KP tumors that do not express engineeredElsevier Inc.antigens. Analyses of other genetically en-
gineered models of murine lung cancer
have revealed very low frequencies of so-
matic point mutations (McFadden et al.,
2014; Westcott et al., 2015), suggesting
that the samemight apply for lung cancers
in the KP model. Taken together, these
data suggest that the robust anti-tumor
T cell responses elicited by Treg cell abla-
tion in the KP model might be directed at
non-mutated self-antigens. If this concept
proves to be widely applicable in different
cancer settings, it suggests that self-spe-
cific T cells could be mobilized to induce
cancer regression, even in cancers associ-
ated with low mutational frequencies.
Moving forward, analysis of the T cell
repertoire in the KP model might provide
insight into the diversity and antigen spec-
ificity of T cells that induce tumor destruc-
tion in this setting and shed light on the
close encounters that shape anti-tumor
immunity.REFERENCES
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